



Commitment letter

To:
European Federation of Pharmaceutical Industries and Associations
EFPIA President Chris Viehbacher and Director General Richard Bergström
Leopold Plaza Building
Rue du Trône 108
B-1050 BRUSSELS
Belgium

Principles for Responsible Clinical Trial Data Sharing

We, leaders of the pharmaceutical industry, believe that:

- Our commitment to data sharing will enhance research and scientific knowledge, advance patient care and improve public health;
- The dramatic increase in the amount of information that research-based companies will make available to researchers will enhance collaborations in the interest of improved research;
- The interests of patients remain at the heart of everything we do in relation to responsible clinical trial data sharing;
- The industry must be allowed to flourish in order to fulfill its promise in serving patients, past, present and future.

On behalf of F. Hoffmann–La Roche Ltd, I hereby confirm our adherence to the Principles for Responsible Clinical Data Sharing launched by PhRMA and EFPIA. We are therefore committed to:

- Establishing policies, procedures or guidelines to reflect the commitments of the Principles;
- Ensuring that relevant employees have received information and training on the Principles; and
- Considering and planning the steps it will take to monitor compliance with the commitments of the Principles on an ongoing basis.

We also adhere to the EFPIA's decision to ensure that an adequate code is in place by mid-2015, which will allow monitoring and oversight of the companies' compliance with the Principles


F.Hoffmann-La Roche Ltd

Signature: 

Daniel O'Day

Chief Operating Officer, Roche Pharmaceuticals
Division and Member of the Roche Corporate
Executive Committee

Date: 26 June 2014

Signature: 

Michael Doherty

Global Head, Roche Pharma Regulatory Affairs

Date: 26 June 2014